专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140005119A1 COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS 审中-公开
标题翻译：用于抑制P110a突变蛋白活性的组合物和方法
公开(公告)号：US20140005119A1
公开(公告)日：2014-01-02
申请号：US13931263
申请日：2013-06-28
申请人： Case Western Reserve University
发明人： Zhengne Wang , Yujun Hao , Chao Wang , Weiping Zheng
IPC分类号： C12N9/12
CPC分类号： C12N9/1205 , A61K38/45 , C12Y207/01153
摘要： A method of inhibiting the activity, signaling, and/or function of a p110α mutant protein in a cancer cell expressing the p110α mutant protein includes administering to the cancer cell an amount of a therapeutic agent effective to inhibit binding of the p110α mutant protein to IRS1 in the cell.
摘要翻译：抑制表达p110alpha突变蛋白的癌细胞中p110alpha突变蛋白的活性，信号传导和/或功能的方法包括向癌细胞施用一定量的有效抑制p110α突变蛋白与IRS1结合的治疗剂在细胞中

2. 发明申请

US20080124310A1 Bead based receptor biology 审中-公开
标题翻译：基于珠的受体生物学
公开(公告)号：US20080124310A1
公开(公告)日：2008-05-29
申请号：US11590967
申请日：2006-11-01
申请人： John G. Marshall , Andrzej Jankowski
发明人： John G. Marshall , Andrzej Jankowski
IPC分类号： A61K38/43 , C12N5/06 , C12Q1/68 , G01N33/53
CPC分类号： G01N33/54313 , A61K31/7105 , A61K38/1709 , C12N15/1135 , C12N15/1137 , C12N2310/14 , C12Y207/01153 , G01N33/5005
摘要： A method for capturing activated receptor signaling complexes from live cells, utilizing bead based biology wherein live cells are contacted with ligand coated beads to form bead binding sites and thereby initiating formation of a ligand-receptor complex at said bead binding site; and a process for distinguishing and confirming non-specifically bound proteins from specifically bound receptor complexes by utilization of one or more methods of biochemical or biophysical analysis, thereby providing, in a preferred embodiment, a utilization of confocal microscopy and proteomic mass spectroscopy.
摘要翻译：一种用于从活细胞捕获活化的受体信号传导复合物的方法，利用基于珠的生物学，其中活细胞与配体包被的珠接触以形成珠结合位点，从而在所述珠粒结合位点引发配体 - 受体复合物的形成; 以及通过利用生物化学或生物物理学分析的一种或多种方法区分和确认非特异性结合的蛋白质与特异性结合的受体复合物的方法，从而在优选实施方案中提供了共焦显微镜和蛋白质组学质谱的利用。

3. 发明申请

US20170283795A1 PHOSPHATIDYLINOSITOL-3-KINASE NUCLEIC ACIDS AND USES THEREOF 审中-公开
公开(公告)号：US20170283795A1
公开(公告)日：2017-10-05
申请号：US15476395
申请日：2017-03-31
申请人： AVIDITY BIOSCIENCES LLC
发明人： Hanhua HUANG
IPC分类号： C12N15/10 , C12N15/113 , C12Q1/68 , G01N33/53 , A61K38/00 , C12N5/00
CPC分类号： C12N15/113 , A61K38/00 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12Q1/6886 , C12Q2600/156 , C12Q2600/158 , C12Q2600/178 , C12Y207/01153 , G01N33/00
摘要： Disclosed herein are molecules and pharmaceutical compositions that mediate RNA interference against PI3K. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that mediate RNA interference against PI3K.

4. 发明申请

US20150284717A1 OLIGOMERS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND UNLOCKED NUCLEOMONOMERS 审中-公开
标题翻译：具有一致限制性单体和解离核子的低聚物
公开(公告)号：US20150284717A1
公开(公告)日：2015-10-08
申请号：US14623498
申请日：2015-02-17
申请人： Marina Biotech, Inc.
发明人： Michael V. Templin , Narendra K. Vaish , Kathy L. Fosnaugh , Shaguna Seth , Michael E. Houston, JR.
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1135 , C12N15/1136 , C12N15/1137 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/3231 , C12N2310/533 , C12N2320/30 , C12N2320/51 , C12Y103/99005 , C12Y203/0102 , C12Y207/01153 , C12Y207/11001 , C12Y207/11021 , C12Y207/11024 , C12Y304/21021
摘要： This invention provides single-stranded and multi-stranded compounds that are useful in various therapeutic modalities to regulate the expression of nucleic acid molecules in a cell. A range of compounds is provided, each containing one or more conformationally restricted nucleomonomers (CRN). In addition, compounds can contain one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (unlocked nucleomonomers, UNA).
摘要翻译：本发明提供可用于调节细胞中核酸分子表达的各种治疗方式的单链和多链化合物。提供了一系列化合物，每种化合物含有一种或多种构象限制的核单体（CRN）。此外，化合物可以含有一个或多个构象限制的核小体单体和一个或多个羟甲基取代的核共聚单体（解开的核单体，UNA）。

5. 发明申请

US20140213630A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING LYMPHOID MALIGNANCY 审中-公开
标题翻译：用于治疗淋巴细胞恶性肿瘤的方法和药物组合物
公开(公告)号：US20140213630A1
公开(公告)日：2014-07-31
申请号：US14003873
申请日：2012-02-29
申请人： Thomas Diacovo
发明人： Thomas Diacovo
IPC分类号： A61K31/52 , A61K31/573 , G01N33/50 , C12Q1/68 , G01N33/573 , A61K31/713 , C12N15/113
CPC分类号： A61K31/52 , A61K31/573 , A61K31/713 , C12N9/1205 , C12N15/1137 , C12Q1/6886 , C12Y207/01137 , C12Y207/01153 , G01N33/5041 , G01N33/573
摘要： The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.
摘要翻译：本发明尤其提供了用于治疗，预防或改善淋巴恶性肿瘤的作用的方法，例如与突变的磷酸酶和张力蛋白同源物（PTEN）基因或T细胞急性成淋巴细胞白血病（T-ALL）相关的那些）。这些方法包括向受试者施用有效量的磷酸肌醇3-激酶-9（PI3Kδ）抑制剂和磷酸肌醇3-激酶-γ（PI3Kγ）抑制剂。本发明还提供了用于治疗淋巴恶性肿瘤的作用的药物组合物。本发明还提供了一种用于鉴定受益于PI3Kδ抑制剂和PI3Kγ抑制剂共同治疗的受试者的方法。该方法包括从受试者的样本中确定受试者是否具有突变的PTEN基因。此外，本发明提供了鉴别具有PI3Kδ和PI3Kγ抑制活性的化合物的方法。

6. 发明申请

US20130190383A1 NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND USES THEREOF 审中-公开
标题翻译：具有一致限制性单体的核酸化合物及其用途
公开(公告)号：US20130190383A1
公开(公告)日：2013-07-25
申请号：US13643180
申请日：2011-04-26
申请人： Narendra K. Vaish , Kathy L. Fosnaugh , Shaguna Seth , Michael E. Houston, JR. , Michael V. Templin
发明人： Narendra K. Vaish , Kathy L. Fosnaugh , Shaguna Seth , Michael E. Houston, JR. , Michael V. Templin
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1135 , C12N15/1136 , C12N15/1137 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/3231 , C12N2310/533 , C12N2320/30 , C12N2320/51 , C12Y103/99005 , C12Y203/0102 , C12Y207/01153 , C12Y207/11001 , C12Y207/11021 , C12Y207/11024 , C12Y304/21021
摘要： This disclosure provides single-stranded and multi-stranded nucleic acid compounds having one or more double-stranded regions that regulate the function or expression of nucleic acid molecules expressed in a cell or a cell regulatory system dependent upon a nucleic acid. The disclosure provides a range of nucleic acid compounds having one or more conformationally restricted nucleomonomers (CRN). Certain nucleic acid compounds may have one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (UNA). The nucleic acid compounds are useful in various therapeutic modalities.
摘要翻译：本公开提供具有调节在细胞中表达的核酸分子的功能或表达的一个或多个双链区域的单链和多链核酸化合物或依赖于核酸的细胞调节系统。本公开提供了一系列具有一个或多个构象限制性核单体（CRN）的核酸化合物。某些核酸化合物可以具有一个或多个构象限制的核小体单体和一个或多个羟甲基取代的核子单体（UNA）。核酸化合物可用于各种治疗方式。

7. 发明申请

US20100278837A1 Compositions And Methods For Reducing Cancer And Inflammation 审中-公开
标题翻译：用于减少癌症和炎症的组合物和方法
公开(公告)号：US20100278837A1
公开(公告)日：2010-11-04
申请号：US12720348
申请日：2010-03-09
申请人： Judith A. Varner , David A. Cheresh , Michael C. Schmid
发明人： Judith A. Varner , David A. Cheresh , Michael C. Schmid
IPC分类号： A61K39/395 , A61K31/713 , A61P35/00
CPC分类号： C07K16/40 , A61K2039/505 , C12N15/1137 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12Y207/01153
摘要： This invention relates to the discovery of the convergence of diverse receptors and signaling pathways on the PI3gamma dependent activation of VLA4 (integrin a4b1). In particular, the invention relates to the role of myeloid cells in tumor inflammation and metastasis. The invention provides methods for inhibiting cancer in a subject comprising administering to a subject having cancer that comprises endothelial cells a therapeutically effective amount of a PI-3-kinase gamma inhibitor that reduces at least one of (a) adhesion of myeloid cells to the endothelial cells, (b) migration of myeloid cells into the cancer, (c) growth of the cancer, (d) activation of integrin a4b1 that is comprised on the myeloid cells, and (e) clustering of integrin a4b1 that is comprised on the myeloid cells.
摘要翻译：本发明涉及多种受体和信号传导途径对VLA4（整联蛋白a4b1）的PI3γ依赖性激活的收敛的发现。特别地，本发明涉及骨髓细胞在肿瘤炎症和转移中的作用。本发明提供了抑制受试者癌症的方法，其包括对具有包含内皮细胞癌症的受试者施用治疗有效量的PI-3-激酶γ抑制剂，其减少以下中的至少一种：（a）骨髓细胞粘附于内皮细胞，（b）骨髓细胞迁移到癌症中，（c）癌症的生长，（d）骨髓细胞上的整合素a4b1的活化，和（e）包含在骨髓中的整联蛋白a4b1的聚集细胞。

8. 发明申请

US20190209570A1 Methods and Pharmaceutical Compositions for Treating Lymphoid Malignancy 审中-公开
公开(公告)号：US20190209570A1
公开(公告)日：2019-07-11
申请号：US16211361
申请日：2018-12-06
申请人： The Trustees of Columbia University in the City of New York
发明人： Thomas DIACOVO
IPC分类号： A61K31/52 , G01N33/573 , G01N33/50 , C12Q1/6886 , C12N15/113 , C12N9/12 , A61K31/573 , A61K31/713
CPC分类号： A61K31/52 , A61K31/573 , A61K31/713 , C12N9/1205 , C12N15/1137 , C12Q1/6886 , C12Y207/01137 , C12Y207/01153 , G01N33/5041 , G01N33/573
摘要： The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.

9. 发明申请

US20180016640A1 PIK3CA NOVEL MUTATIONS DETECTION FOR DIAGNOSIS OF ACQUIRED CETUXIMAB RESISTANCE IN METASTATIC COLORECTAL CANCER PATIENTS 审中-公开
公开(公告)号：US20180016640A1
公开(公告)日：2018-01-18
申请号：US15525922
申请日：2015-11-06
申请人： AFFILIATED HOSPITAL, ACADEMY OF MILITARY MEDICAL SCIENCES
发明人： Jianming XU , Yan WANG , Yan WANG
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q1/68 , C12Q2600/106 , C12Q2600/156 , C12Y207/01153
摘要： Disclosed is a kit for detecting drug resistance of cetuximab in the treatment of metastatic colorectal cancer. The kit comprises a substance used for detecting gene mutations in Exon 19 of the PIK3CA gene, and may further comprise a specification recording the following contents: if Exon 19 in the PIK3CA gene of a patient with metastatic colorectal cancer as a subject to be tested, who is intended to receive cetuximab treatment or is receiving cetuximab treatment and does not have drug resistance, has at least one of K944N, F930S, V955G, V955I, and K966E mutations, the subject to be tested will develop drug resistance or will be a candidate to develop drug resistance when receiving or continuing to receive cetuximab for treating metastatic colorectal cancer.

10. 发明申请

US20170246173A1 Methods and Pharmaceutical Compositions for Treating Lymphoid Malignancy 审中-公开
公开(公告)号：US20170246173A1
公开(公告)日：2017-08-31
申请号：US15451306
申请日：2017-03-06
申请人： The Trustees of Columbia University in the City of New York
发明人： Thomas DIACOVO
IPC分类号： A61K31/52 , G01N33/573 , A61K31/573 , C12N15/113 , C12Q1/68 , G01N33/50 , C12N9/12 , A61K31/713
CPC分类号： A61K31/52 , A61K31/573 , A61K31/713 , C12N9/1205 , C12N15/1137 , C12Q1/6886 , C12Y207/01137 , C12Y207/01153 , G01N33/5041 , G01N33/573
摘要： The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式